Blood Test and Tau-Targeting Therapy Show Promise for Alzheimer's Detection and Treatment

Blood tests measuring the p-tau217 protein could predict Alzheimer's risk years before symptoms appear, while a new experimental therapy targeting tau shows potential to slow progression. Two major studies presented at the Alzheimer's Association International Conference (AAIC) in London have advanced the field.

Blood Test for Early Detection

A study published in JAMA found that high levels of p-tau217 in cognitively healthy older adults were associated with a 38% higher risk of developing early dementia within five years, and up to 78% higher risk over ten years Source: CNN. The test could help predict individual risk and aid primary care physicians, improving diagnostic accuracy from 62% to 88% Source: Infobae. However, clinical guidelines currently discourage testing in asymptomatic individuals outside research settings Source: Heraldo.

Tau-Targeting Therapy

Another study presented at AAIC tested the experimental drug diranersen (BIIB080), designed to reduce tau production. Researchers observed significant reduction in tau levels and signs of slowed cognitive decline, especially at the lowest dose Source: Infobae (second). This shifts focus from amyloid-beta, the target of current approved drugs, to tau Source: Infobae (second). Dr. Mercè Boada of Ace Alzheimer Center Barcelona called it "hopeful news" but urged caution pending further data Source: Infobae (second).

Cautions and Next Steps

Experts emphasize that blood tests should not be used alone; they provide only part of the biological picture . The test is most useful in people with cognitive symptoms, not healthy individuals. The therapy requires more research. Both approaches aim to transform Alzheimer's from a devastating disease to one that can be treated early.